Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
22/09/2026 14:00
BRIEF-Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile Sept 22 (Reuters) - Ionis Pharmaceuticals, Inc. IONS.O:
IONIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 FUSION STUDY OF ULEFNERSEN MARKING SIGNIFICANT MILESTONE IN ADVANCING FIRST POTENTIAL DISEASE MODIFYING TREATMENT FOR FUS-ALS
IONIS PHARMACEUTICALS, - ULEFNERSEN DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT ON PRIMARY ENDPOINT IN FUS-ALS
IONIS PHARMACEUTICALS, - ULEFNERSEN DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nBw52KTvpa
Further company coverage: IONS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study